To evaluate cortisol response to an acute IL‐2 injection in healthy subjects and metastatic cancer patients, to standardise a clinical neuro‐endocrino‐immune test capable of documenting possible alterations of the link between neuroendocrine and immune systems. This evidence concerns the gene IL2 and metastatic malignant neoplasm.